ALEMBIC DEFERASIROX deferasirox 360 mg film-coated tablet blister pack

Kraj: Australia

Język: angielski

Źródło: Department of Health (Therapeutic Goods Administration)

Składnik aktywny:

deferasirox, Quantity: 360 mg

Dostępny od:

Alembic Pharmaceuticals Australia Pty Ltd

Forma farmaceutyczna:

Tablet, film coated

Skład:

Excipient Ingredients: colloidal anhydrous silica; magnesium stearate; crospovidone; sodium starch glycollate type A; microcrystalline cellulose; poloxamer; povidone; titanium dioxide; hypromellose; purified talc; macrogol 4000; indigo carmine aluminium lake

Droga podania:

Oral

Sztuk w opakowaniu:

30

Typ recepty:

(S4) Prescription Only Medicine

Wskazania:

The treatment of chronic iron overload due to blood transfusions (transfusional haemosiderosis) in adults and paediatric patients 6 years and older. ALEMBIC DEFERASIROX is also indicated for the treatment of chronic iron overload in paediatric patients aged 2 to 5 years who are unable to take desferrioxamine therapy or in whom desferrioxamine has proven ineffective. ,ALEMBIC DEFERASIROX is also indicated for the treatment of chronic iron overload in patients with non-transfusion- dependent thalassemia syndromes aged 10 years and older.

Podsumowanie produktu:

Visual Identification: Dark blue, oval, biconvex, film-coated tablet with beveled edges, debossed with "L" on one side and "665" on the other side. Approximately 17 mm in length and approximately 7 mm in width.; Container Type: Blister Pack; Container Material: PVC/PVDC/Al; Container Life Time: 36 Months; Container Temperature: Store below 25 degrees Celsius; Container Closure: Neither child resistant closure nor restricted flow insert

Status autoryzacji:

Registered

Data autoryzacji:

2020-11-16